摘要
目的观察复方玄驹胶囊治疗慢性非细菌性前列腺炎(CNP)并发勃起功能障碍(ED)的临床疗效与安全性。方法符合试验入选标准的患者40例口服复方玄驹胶囊:每次3粒,tid,治疗4周,采用自身对照的方法,根据服药前后各项指标的变化情况评价疗效。结果治疗前后各项指标比较,差异均有显著性(P<0.05),治疗4周后NIH-CPSI总分、疼痛与不适评分、排尿症状评分及生活质量评分评分较治疗前分别下降了11.03(49.13%),6.27(47.21%),2.11(47.2%),4.21(47.09%);轻、中、重度勃起功能障碍国际勃起功能指数(IIEF-5)评分分别增加5.4(35.06%),6.21(67.79%),5.84(103.18%)。治疗4周后CNP的治愈率为32.5%,有效率为85.0%;ED的治愈率为30.0%,有效率为87.5%。全组患者在观察过程中有出现轻度头晕1例,大便干结2例,心慌1例,其他无不良反应。结论复方玄驹胶囊是治疗慢性非细菌性前列腺炎并发勃起功能障碍的有效药物,且安全性高。
Objective To evaluate the efficacy and safety of compound xuanju capsule（ CXJC） in the treatment of chronic nonbacterial prostatitis（ CNP） with erectile dysfunction（ ED） . Methods 40 eligible outpatients with NIH-CNP and ED were treated with CXJC at 3 capsules per times,tid for 4 weeks. The efficacy was evaluated by self-control comparison,according to changes of various indexes after treatment. Results After 4-week therapy,the NIH-CPSI overall scores,and pain,urinary,and quality of life subscores were reduced by 11. 03 points（ 49. 13% ） ,6. 27 points（ 47. 21% ） ,2. 11 points（ 47. 2% ） ,and 4. 21 points （ 47.09%） ,respectively. IIEF-5 was increased by 5. 4 points（ 35. 06%） ,6. 21 points（ 67. 79%） ,and 5.84 points（ 103. 18%） , respectively in the subgroups of ED （ mild,moderate,severe level） . Recovery and effective rates of CNP were 32. 5% （ 13/40） and 85. 0% （ 34/40） ,and the rates of ED were 30. 0% （ 12/40） and 87. 5% （ 35/40） respectively. No severe adverse reaction associated with medication was observed execept for 1case of mild dizziness,2cases of dry stool and 1case of flustered. Conclusion CXJC is effective and safe for the treatment of chronic nonbacterial prostatitis with erectile dysfunction.
出处
《医药导报》
CAS
2010年第8期1022-1024,共3页
Herald of Medicine
基金
杭州市131人才培养基金(基金编号:HZ131-2007)
